Market Research Report
Global Plasma Protease C1-Inhibitor Treatment Market - 2020-2027
|Published by||DataM Intelligence||Product code||1004498|
|Published||Content info||180 Pages
Delivery time: 2 business days
|Global Plasma Protease C1-Inhibitor Treatment Market - 2020-2027|
|Published: May 10, 2021||Content info: 180 Pages||
C1-INH is a type of potent inhibitor of the complement and direct contact activation systems, and its deficiency can lead to the manifestation of hereditary angioedema. Moreover, Replacement therapy with human plasma-derived C1-INH is an efficacious and safe treatment for this disease.
The global plasma protease C1-inhibitor treatment market size was worth US$ XX billion in 2020 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).
The plasma protease C1-inhibitor treatment market is driven with a significant growth over the forecast period due to the growing incidence of the disease hereditary angioedema (HAE). As per the global umbrella organization for the world's HAE patient groups , Hereditary angioedema is a life-threatening genetic disease with incidence between 1 in 10,000 and 1 in 50,000 people according to HAE International (HAEi). Moreover, increasing R&D investments, discovery of inhibitor drugs, rising product approvals promising pipeline drugs and novel therapies for the treatment of hereditary angioedema are the few other factors driving the market globally.
Increasing Prevalence of Hereditary Angioedema (HAE)
Hereditary angioedema (HAE) is an autosomal dominant, life-threatening condition, manifesting as recurrent and self-limiting episodes of facial, laryngeal, genital, or peripheral swelling with abdominal pain secondary to intra-abdominal edema. Additionally, the availability of various treatment options for acute attacks and prophylaxis of HAE which are authorized and available in the market. Moreover, HAE causes humanistic burden to patients, affecting both physical and mental health, which has a negative impact on education, career, and work productivity, and with substantial economic burdens. Hence, the timely and proper use of disease-specific treatments could improve the patients' quality of life and reduce the disease-specific morbidity and mortality. Therefore, reducing costs associated with hospitalizations and emergency room visits.
Increasing Investments in the Research & Development Activities
There is rapid expansion in the R&D activities that key market players are involved in for the development of new C1-inhibitor deficiency drugs. This had led to the overall increase of the market growth during forecast period.
COVID-19 Impact Analysis
COVID-19 pandemic affected the economy globally. COVID 19 has directly affected production and demand, supply chain disruption, and financial impact. Moreover, COVID-19 has directly impacted the manufacturers' supply chain across worldwide and shut down the production facilities to minimize the risk of virus spread. Also, the lockdown policies have strengthened the demand for various raw materials. There are various research institutes and biopharmaceutical companies who are engaged in study the effects of plasma protease C1-inhibitors in treating significant systemic abnormalities in patients with COVID-19. In April 2020, Pharming Group N.V. announced the encouraging results from five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia that were treated with RUCONEST (recombinant human C1 inhibitor) under a compassionate use program at the University Hospital Basel, Switzerland.
Thus, such positive results of the plasma protease C1-inhibitors in treating COVID-19 patients is anticipated to provide a significant growth opportunity for Plasma Protease C1-inhibitor Treatment Market.
Based on the drug type, the plasma protease C1-Inhibitor treatment market has been classified into C1-inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor and Antagonist.
Autolyzed segment accounted for the highest market share in the global market
Among drug type, C1-inhibitor segment is expected to hold a dominant position in the plasma protease C1-inhibitor treatment market, due to the robust number of drugs approved by the regulatory agencies. For instance, in June 2017, CSL Behring, a global biopharmaceutical company, received the U.S. Food and Drug Administration for HAEGARDA (C1 Esterase Inhibitor Subcutaneous (Human))
Based on the dosage type, the plasma protease C1-Inhibitor treatment market has been classified into lyophilized and liquid/injectable.
Lyophilized segment dominated the Global Plasma Protease C1-Inhibitor Treatment Market in 2019
lyophilized segment holds the leading market share in on the back of increasing practice of intravenous administration of drugs for the treatment of HAE. Furthermore, rising demand for intravenous C1 esterase inhibitor drugs in emerging markets of regions like Asia Pacific and Latin America is expected to positively influence the lyophilized segment.
Although, the liquid/injectable segment is likely to hold significant market share in the near future due to several factors. This includes increasing demand for subcutaneous administration of drugs, cost effectiveness, less adverse effects, and increased preference for Firazyr over Kalbitor by physicians. However, the expected launch of subcutaneous Cinryze, Berinert, and DX-2930 will further hamper the growth of lyophilized segment. To stay competitive, companies are vying to introduce the subcutaneous variants of Cinryze and Berinet for prophylactic treatment and are expected to be commercially available by 2019 and 2018 respectively. Despite the liquid/injectable nature of Firazyr and Kalbitor the side-effects associated with them can hamper the liquid/injectable segment over the forecast period.
Based on geography, the study analyzes the Plasma Protease C1-Inhibitor Treatment Market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
North America leads the global market throughout the forecast period.
North America holds the largest share in the global Plasma Protease C1-inhibitor market due to the rising Hereditary Angioedema (HAE) and increasing R&D investments. The other factors also include presence of well-established healthcare infrastructure, an increasing number of product approvals, and major market players providing effective treatment options to the patients suffering from Hereditary Angioedema in North America.
According to Discover HAE, it is estimated that 6,000 people in the United States live with HAE currently. In June 2017, CSL Behring received U.S. Food and Drug Administration (FDA) approval for its HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients. Hence all these factors are expected to drive the overall market in the United States.
The plasma protease C1-inhibitor treatment market is highly competitive, owing to the presence of brands. The key plasma protease C1-inhibitor treatment market players which are contributing to the growth of the global market includes Limited (CSL Behring LLC), Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings), Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Inc., Fresenius Kabi. The major players are adopting new product launch and expansion strategies for global growth in the Plasma Protease C1-Inhibitor Treatment Market
Overview: CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products and providing them to people in more than 100 countries. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies (PIDD); hereditary angioedema; inherited respiratory disease; and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.
Product Portfolio: The Company's portfolio comprises of plasma protease C1-Inhibitor treatment
The global plasma protease C1-inhibitor treatment market report would provide access to an approx. 42 market data table, 46 figures and 273 pages.
LIST NOT EXHAUSTIVE